Bristol-Myers Squibb (BMY) Shares Pop as Ipilimumab Reaches Primary Endpoint
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Price: $78.23 +1.72%
Overall Analyst Rating:
NEUTRAL (
Down)
Dividend Yield: 3%
Revenue Growth %: +5.0%
Overall Analyst Rating:
NEUTRAL (
Down)Dividend Yield: 3%
Revenue Growth %: +5.0%
Trade Now!
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) shares are popping after-hours today following an announcement that ipilimumab clinical trial met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma. Shares are up 4.9% post-market.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at Wells Fargo
- Bristol-Myers Squibb (BMY) Sells Manufacturing Facility in East Syracuse, New York to LOTTE
- Here's Which 3 Tech Stocks Hedge Funds Were Selling the Most in Q1
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
